ChemoCentryx (NASDAQ: CCXI) and Strongbridge Biopharma PLC (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.


This table compares ChemoCentryx and Strongbridge Biopharma PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A -62.62% -20.58%
Strongbridge Biopharma PLC N/A -83.83% -34.77%

Valuation and Earnings

This table compares ChemoCentryx and Strongbridge Biopharma PLC’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ChemoCentryx $26.31 million 14.15 -$30.76 million ($0.62) -12.47
Strongbridge Biopharma PLC $1.53 million 145.50 -$39.43 million ($2.78) -2.27

ChemoCentryx has higher revenue and earnings than Strongbridge Biopharma PLC. ChemoCentryx is trading at a lower price-to-earnings ratio than Strongbridge Biopharma PLC, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for ChemoCentryx and Strongbridge Biopharma PLC, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 1 0 2.50
Strongbridge Biopharma PLC 0 0 3 0 3.00

Strongbridge Biopharma PLC has a consensus price target of $13.33, indicating a potential upside of 111.64%. Given Strongbridge Biopharma PLC’s stronger consensus rating and higher possible upside, analysts clearly believe Strongbridge Biopharma PLC is more favorable than ChemoCentryx.

Volatility & Risk

ChemoCentryx has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma PLC has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500.

Institutional and Insider Ownership

50.1% of ChemoCentryx shares are owned by institutional investors. Comparatively, 62.8% of Strongbridge Biopharma PLC shares are owned by institutional investors. 26.8% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ChemoCentryx Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with's FREE daily email newsletter.